** Shares in Ion Beam Applications IBAB.BR rise more than 3% after the Belgian radiation therapy and radiopharmaceuticals equipment company announced the acquisition of radiochemistry firm ORA
** IBA says the deal, worth between 15 million and 20 million euros ($17.6 million and $23.4 million), will not have a material impact on the 2025 and mid-term guidance
** The acquisition is not expected to have a meaningful impact on IBA's financials, KBC Securities also notes
** Still, the brokerage says IBA "further strengthens its position as an integrated player in the nuclear medicine market, ranging from radioisotope production, to cyclotrons and synthesize"
** Shares of IBA are trading at up to 12.4 euros, their highest since late July
($1 = 0.8540 euros)
(Reporting by Gianluca Lo Nostro)
((gianluca.lonostro@thomsonreuters.com;))